Ventyx Biosciences Inc. (NASDAQ:VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232.

Check out the current price of VTYX stock here. 

Phase 2 Data

In a study involving 175 participants, VTX3232 monotherapy led to a 78% reduction in hsCRP levels at week 12 compared to baseline, while the placebo group saw a 3% increase, according to the company's announcement. This result was statistically significant (p<0.0001) in the modified analysis set. High-Sensitivity C-reactive Protein is a blood test that detects even small amounts of C-reactive protein to help evaluate an individual's risk of developing cardiovascular disease.

In the full analysis set, VTX3232 showed a 64% reduction in hsCRP, compared to a 3% ...